NYX‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults

NYX‐2925, a new chemical entity, acts as a co‐agonist to glutamate at the N‐methyl‐D‐aspartate receptor (NMDAR). At low concentrations of endogenous agonists (glycine/D‐serine), NYX‐2925 partially activates NMDARs, modulating neural pathways relevant for chronic pain. NYX‐2925 is being developed for...

Descripción completa

Detalles Bibliográficos
Autores principales: Houck, David R., Sindelar, Laurel, Sanabria, Carlos R., Stanworth, Stephanie H., Krueger, Maggie, Suh, Mary, Madsen, Torsten M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440576/
https://www.ncbi.nlm.nih.gov/pubmed/30242962
http://dx.doi.org/10.1111/cts.12584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440576/
https://www.ncbi.nlm.nih.gov/pubmed/30242962
http://dx.doi.org/10.1111/cts.12584

Ejemplares similares